This is a summary of the European public assessment report (EPAR) for Clopidogrel TAD. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Clopidogrel TAD. For practical information about using Clopidogrel TAD, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Clopidogrel is indicated in adults for the prevention of atherothrombotic events in: - Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
Therapeutic Area (MeSH)
ATC Code
B01AC04
ATC Item
clopidogrel
Pharmacotherapeutic Group
Antithrombotic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| clopidogrel (as hydrochloride) | N/A | clopidogrel (as hydrochloride) |
EMA Name
Clopidogrel TAD
Medicine Name
Clopidogrel TAD
Aliases
N/ANo risk management plan link.
